Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Frederic Colombel

Showing results (41-50 of 462) with videos related to

Pageof 47
Sort By:
Virulence|March 26, 2024
Coincidence of antibodies against Hwp1 and ASCA, two distinct molecular targets of <i>Candida albicans</i>, reinforces the link between this fungal species and coeliac diseaseBoualem Sendid, Christopher Cao, Jean-Frederic Colombel, et al.
The Lancet. Gastroenterology & Hepatology|June 13, 2024
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trialJack Satsangi, Jan Nowak, Rahul Kalla, et al.
Expert Review of Gastroenterology & Hepatology|May 25, 2018
Clinical updates on perianal fistulas in Crohn's diseaseOri Rackovsky, Robert Hirten, Ryan Ungaro, et al.
Journal of Crohn'S & Colitis|April 13, 2026
Crohn's disease is an obstructive lymphangitisHerbert J Van Kruiningen, Jean-Frederic Colombel, Pietro Tonelli
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2025
Advanced Therapies in Crohn's Disease: A Critical Appraisal of Location-based EfficacyAshkan Rezazadeh Ardabili, Catherine Le Berre, Jean-Frederic Colombel
Expert Opinion on Pharmacotherapy|May 3, 2022
An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitisCatherine Rowan, Ryan Ungaro, Saurabh Mehandru, et al.
Gastroenterology|May 7, 2021
Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel DiseaseCarlos Stalgis, Parakkal Deepak, Saurabh Mehandru, et al.
Clinical and Translational Gastroenterology|January 8, 2016
Loss of Response to Anti-TNFs: Definition, Epidemiology, and ManagementGiulia Roda, Bindia Jharap, Narula Neeraj, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 14, 2006
Advances and perspectives in the genetics of inflammatory bowel diseasesMathias Chamaillard, Razvan Iacob, Pierre Desreumaux, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 26, 2009
Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's diseaseLaurent Peyrin-Biroulet, Jean-Frederic Colombel, William J Sandborn
Pageof 47

Showing results (41-50 of 462) with videos related to

Sort By:
Pageof 47
Virulence|March 26, 2024
Coincidence of antibodies against Hwp1 and ASCA, two distinct molecular targets of <i>Candida albicans</i>, reinforces the link between this fungal species and coeliac diseaseBoualem Sendid, Christopher Cao, Jean-Frederic Colombel, et al.
The Lancet. Gastroenterology & Hepatology|June 13, 2024
Treatment strategies and biomarkers in Crohn's disease: the PROFILE trialJack Satsangi, Jan Nowak, Rahul Kalla, et al.
Expert Review of Gastroenterology & Hepatology|May 25, 2018
Clinical updates on perianal fistulas in Crohn's diseaseOri Rackovsky, Robert Hirten, Ryan Ungaro, et al.
Journal of Crohn'S & Colitis|April 13, 2026
Crohn's disease is an obstructive lymphangitisHerbert J Van Kruiningen, Jean-Frederic Colombel, Pietro Tonelli
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 24, 2025
Advanced Therapies in Crohn's Disease: A Critical Appraisal of Location-based EfficacyAshkan Rezazadeh Ardabili, Catherine Le Berre, Jean-Frederic Colombel
Expert Opinion on Pharmacotherapy|May 3, 2022
An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitisCatherine Rowan, Ryan Ungaro, Saurabh Mehandru, et al.
Gastroenterology|May 7, 2021
Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel DiseaseCarlos Stalgis, Parakkal Deepak, Saurabh Mehandru, et al.
Clinical and Translational Gastroenterology|January 8, 2016
Loss of Response to Anti-TNFs: Definition, Epidemiology, and ManagementGiulia Roda, Bindia Jharap, Narula Neeraj, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 14, 2006
Advances and perspectives in the genetics of inflammatory bowel diseasesMathias Chamaillard, Razvan Iacob, Pierre Desreumaux, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 26, 2009
Insufficient evidence to conclude whether anti-tumor necrosis factor therapy increases the risk of lymphoma in Crohn's diseaseLaurent Peyrin-Biroulet, Jean-Frederic Colombel, William J Sandborn
Pageof 47